Avatar universal

Arrowhead Results

Just read this article about Arrowhead. It states significant hbsag knockdown.


Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™
April 12, 2019 12:45 PM Eastern Daylight Time
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV), a third-generation subcutaneously administered RNA interference (RNAi) therapeutic candidate being developed as a potential treatment for patients with chronic hepatitis B virus (HBV) infection, at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL).

Arrowhead entered into a license agreement in October 2018 with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize ARO-HBV.

Key results from this interim analysis include the following:

JNJ-3989 rapidly reduced hepatitis B surface antigen (HBsAg) in patients that had 24 weeks or more of HBsAg assay results (n=40) to thresholds possibly associated with improved chances of HBsAg seroclearance1 in many patients, after only 3 doses
100% of patients (40 of 40) achieved ≥1.0 Log10 IU/mL HBsAg reduction
88% of patients (35 of 40) achieved HBsAg <100 IU/mL
43% of patients (17 of 40) achieved HBsAg <10 IU/mL
13% of patients (5 of 40) achieved HBsAg <1 IU/mL
JNJ-3989 reduced all measurable viral products, including HBsAg in hepatitis B e-antigen (HBeAg) positive or HBeAg negative patients
JNJ-3989 administered subcutaneously was well tolerated at doses up to 400 mg in all chronic hepatitis B (CHB) patients in cohorts 2b-11 (n=56)
168 total doses administered to 56 CHB patients (cohorts 2b through 11)
No drug related serious adverse events (SAE) reported
Unrelated SAE of menorrhagia
Unrelated SAE of anxiety/depression
All patients received all 3 scheduled doses; No dropouts
No dose related pattern of adverse changes in laboratory values (e.g. ALT, AST, total bilirubin, creatinine)
17 total AEs at injection site (10% of injections) reported (e.g. erythema, tenderness, bruising), all were mild
Oral Presentation Details:

Short term RNA interference (RNAi) therapy in chronic hepatitis B (CHB) using JNJ-3989 brings majority of patients to HBsAg <100 IU/ml

Presentation Reference: PS-080
Session: Parallel session: Hepatitis B - drug development
Session Date and Time: April 12, 2019 at 5:45 p.m. CET
Authors: Man-Fung Yuen, et al.
Additional details, including the presentation abstract, can be found on the ILC website at https://ilc-congress.eu/. A copy of presentation materials can be accessed by visiting the Events section under the Investors tab of the Arrowhead website.

AROHBV1001 (NCT03365947) is a Phase 1/2 clinical study evaluating the safety, tolerability, and pharmacokinetic effects of single-ascending doses (SAD) of ARO-HBV in healthy adult volunteers, as well as the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses (MAD) of ARO-HBV in patients with chronic HBV.

Hepatitis B infection is a life-threatening viral infection of the liver, which can cause cirrhosis — scarring of liver tissue — and liver cancer if the infection becomes chronic. The World Health Organization cites that hepatitis B is a global public health problem with 257 million people living with the disease, resulting in 887,000 deaths in 2015.2 While a preventive vaccine is available, cure rates for those infected remain low and most patients will endure lifelong therapy.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.
5 Responses
Avatar universal
Studyforhope had mentioned that the reduction is not enough to create an immune response, maybe Interferon or Tymosin Alpha would be needed, and that after stopping ARO-HBV the HBSAG would return and that the HBV virus reproduces a lot so it can remain, something along those lines.


Here is the link
Avatar universal
not that great none cleared hbsag, this drug alone is useless they must push hbsag to undetectable and then it is possible that zadaxin/pegintf might work to make hbsab.the drug must have same results as replicor to have some cure rates, 100% were not achieved by replicor too so much more is needed
I think until there is a functional cure, everyone should go on TAF and just keep the virus from replicating that way there is no Cirrhosis, and it reduces further HBVDNA integration in to the host genome. This would be like taking a blood pressure medication or a cholesterol medication daily.
Avatar universal
hopefully higher doses or 48weeks treatment can make hbsag und and high hbsab
Avatar universal
Unfortunately, HbsAg reduction without the development of anti-Hbs that exceeds the hbsag is incomplete. As long as the HBV virus is integrated within the genome of the hepatocytes, it will maintain the chronic hepatittis B infection. The solution, in my opinion, is to make the host immune system react to the chronic infection by developing anti-hbs, and/or directly target the cccDNA and integrated viral DNA genes within the hepatocytes.
Avatar universal
My doctor is giving me a option to start a clinical trial and he mentioned that it will be taf / (clinical) . It will be liquid form and after a certain amount of time , I will go off taf / (clincical) while checking my hbsag / hbvdna. My doctor is in the pasadena area and arrow pharm is also in the pasadena area, I think my trial might be  jnj-3989 but it was not announced to me yet. My last hbsag quant test was 850 iu/ml so that might of made me a good candidate for their trial under 1000 iu/ml. i will keep you guys posted when i start.
Thank you, please keep us informed.
Any update?
Have an Answer?

You are reading content posted in the Hepatitis B Community

Didn't find the answer you were looking for?
Ask a question
Popular Resources
The first signs of HIV may feel like the flu, with aches and a fever.
Frequency of HIV testing depends on your risk.
Post-exposure prophylaxis (PEP) may help prevent HIV infection.
Millions of people are diagnosed with STDs in the U.S. each year.
STDs can't be transmitted by casual contact, like hugging or touching.
Syphilis is an STD that is transmitted by oral, genital and anal sex.